A Review On Benzimidazole Derivatives As Cytotoxic Agents Against Human Colorectal Cancer Cells (HCT116)

The human colorectal carcinoma cell line HCT116 is one of the most extensively utilized in vitro experimental models in cancer biology and anticancer drug discovery. Since its establishment from the primary colon carcinoma of an adult male patient, HCT116 cells have become indispensable for evaluating the biological activity of newly synthesized compounds, particularly heterocyclic molecules such as benzimidazole derivatives. Their stable genetic profile, rapid proliferation rate, reproducibility, and molecular resemblance to human colorectal tumors make them one of the preferred models for investigating tumor biology, drug mechanisms, and therapeutic responses.

HCT116 cells closely mimic the molecular alterations observed in colorectal cancer patients, including constitutive activation of oncogenic signaling pathways, deregulated cell-cycle progression, enhanced proliferative capacity, and altered apoptotic mechanisms. Consequently, these cells provide an excellent platform for screening novel chemotherapeutic agents before progressing to animal studies and clinical investigations.

Origin and Characteristics of HCT116 Cells

HCT116 cells were established from the primary colon carcinoma of a 48-year-old male patient diagnosed with colorectal adenocarcinoma. The cells exhibit an epithelial morphology and grow as adherent monolayers under standard tissue culture conditions. They possess a doubling time of approximately 20–24 hours, allowing rapid experimental evaluation of cytotoxic compounds.

One of the major advantages of HCT116 cells is their high reproducibility under laboratory conditions. These cells can be cultured efficiently in McCoy’s 5A medium supplemented with fetal bovine serum and antibiotics while maintaining stable genetic characteristics over multiple passages.

Morphologically, HCT116 cells appear polygonal with distinct epithelial features. They exhibit strong proliferative potential, anchorage-dependent growth, and the ability to form colonies in soft agar assays. These characteristics make them highly suitable for evaluating antiproliferative and cytotoxic effects of newly synthesized benzimidazole derivatives.

Genetic Characteristics

The molecular profile of HCT116 cells resembles that of aggressive colorectal tumors, making them highly valuable in translational cancer research. The most important genetic characteristics include mutations in KRAS, activation of the Wnt/β-catenin signaling pathway, and defects in the DNA mismatch repair (MMR) system resulting in microsatellite instability (MSI).

HCT116 cells harbor an activating mutation in the KRAS oncogene, leading to constitutive stimulation of the MAPK signaling cascade. This mutation promotes uncontrolled cellular proliferation and contributes to resistance against several epidermal growth factor receptor (EGFR)-targeted therapies. Consequently, HCT116 cells are frequently employed to evaluate compounds capable of overcoming KRAS-mediated drug resistance.

Another hallmark feature is the mutation of β-catenin (CTNNB1), resulting in persistent activation of Wnt signaling. This pathway regulates genes associated with cellular proliferation, stemness, and tumor progression. Aberrant β-catenin signaling contributes significantly to colorectal carcinogenesis and serves as an important therapeutic target for novel benzimidazole derivatives.

HCT116 cells are also deficient in the MLH1 mismatch repair gene, leading to microsatellite instability (MSI). This defect causes accumulation of genetic mutations and genomic instability, closely resembling a subset of colorectal cancers observed clinically.

Despite these alterations, HCT116 cells retain wild-type TP53, allowing researchers to investigate apoptosis mediated through functional p53 signaling pathways. This characteristic distinguishes HCT116 cells from several other colorectal cancer cell lines that possess mutant TP53.

Advantages of HCT116 Cells in Drug Discovery

Several biological characteristics make HCT116 one of the preferred colorectal cancer models.

The cells exhibit rapid proliferation, enabling efficient evaluation of cytotoxic compounds within relatively short experimental periods. Their stable phenotype minimizes experimental variability and enhances reproducibility across laboratories.

The presence of clinically relevant genetic mutations allows accurate prediction of therapeutic responses against human colorectal tumors. HCT116 cells also demonstrate high sensitivity toward DNA-damaging agents, microtubule inhibitors, kinase inhibitors, and apoptosis-inducing compounds.

Furthermore, these cells are highly amenable to molecular biology techniques including RNA interference, CRISPR-Cas9 gene editing, quantitative PCR, Western blotting, transcriptomic analysis, proteomics, metabolomics, and fluorescence imaging. Such versatility facilitates comprehensive mechanistic investigations following treatment with newly synthesized benzimidazole derivatives.

Applications in Anticancer Research

HCT116 cells have become a standard experimental model for evaluating the anticancer potential of synthetic heterocyclic compounds. Medicinal chemists routinely employ these cells during early-stage drug discovery to identify lead molecules exhibiting potent cytotoxic activity.

Several biological endpoints can be investigated using HCT116 cells, including inhibition of cell proliferation, induction of apoptosis, disruption of mitochondrial membrane potential, generation of reactive oxygen species (ROS), inhibition of angiogenesis-related signaling, suppression of metastatic behavior, and modulation of oncogenic signaling pathways.

In addition to evaluating direct cytotoxicity, HCT116 cells are widely used to investigate multidrug resistance, synergistic drug combinations, nanoparticle-mediated drug delivery, photodynamic therapy, gene therapy, and targeted molecular therapies.

Cytotoxicity Assays

MTT Assay

The MTT assay remains the most widely used colorimetric method for evaluating cell viability following treatment with benzimidazole derivatives. Viable cells convert the yellow tetrazolium salt into purple formazan crystals through mitochondrial succinate dehydrogenase activity. Reduction in absorbance directly reflects decreased cell viability, allowing calculation of ICâ‚…â‚€ values.

Sulforhodamine B (SRB) Assay

The SRB assay measures total cellular protein content as an indicator of cell density and proliferation. Following treatment, cells are fixed with trichloroacetic acid and stained with sulforhodamine B dye. Absorbance is proportional to the number of viable cells and provides highly reproducible results.

CCK-8 Assay

The Cell Counting Kit-8 (CCK-8) assay utilizes a water-soluble tetrazolium salt that is converted into an orange-colored product by viable cells. Compared with MTT, CCK-8 is more sensitive, less toxic, and does not require crystal dissolution.

Live/Dead Cell Assay

Fluorescent dyes such as calcein-AM and propidium iodide distinguish viable from non-viable cells. Live cells fluoresce green, whereas dead cells exhibit red fluorescence due to compromised membrane integrity. cytotoxicity assays in a summary table1

Fig 1: Molecular mechanisms of benzimidazole derivatives inducing cytotoxicity in HCT116 colorectal cancer cells."

Importance of HCT116 in Benzimidazole Research

The HCT116 cell line has become one of the most valuable experimental models for evaluating the cytotoxic potential of benzimidazole derivatives. Numerous studies have demonstrated that structural modification of the benzimidazole scaffold significantly enhances antiproliferative activity against HCT116 cells through multiple mechanisms, including apoptosis induction, inhibition of tubulin polymerization, suppression of PI3K/Akt signaling, ROS-mediated oxidative stress, and cell-cycle arrest. Because HCT116 cells possess clinically relevant genetic alterations and exhibit reproducible responses to chemotherapeutic agents, they provide an excellent platform for identifying promising lead compounds for colorectal cancer therapy. Consequently, continued utilization of HCT116 cells in medicinal chemistry and pharmacological research is expected to accelerate the development of next-generation benzimidazole-based anticancer agents with improved efficacy and safety profiles.

REFERENCES

1. Brattain MG, Fine WD, Khaled FM, Thompson J, Brattain DE. Heterogeneity of malignant cells from a human colonic carcinoma. Cancer Research. 1981;41:1751–1756.
2. Ahmed D, Eide PW, Eilertsen IA, et al. Epigenetic and genetic features of colorectal cancer cell lines. Nature Communications. 2013;4:1519.
3. Berg KCG, Eide PW, Eilertsen IA, et al. Multi-omics of colorectal cancer cell lines. Nature Scientific Data. 2017;4:170218.
4. Sveen A, Kopetz S, Lothe RA. Biomarker-guided therapy for colorectal cancer. Nature Reviews Clinical Oncology. 2020;17:595–610.
5. Guinney J, Dienstmann R, Wang X, et al. The consensus molecular subtypes of colorectal cancer. Nature Medicine. 2015;21:1350–1356.
6. National Cancer Institute. HCT116 Cell Line Fact Sheet.
7. ATCC. HCT116 (CCL-247™): Product Information and Cell Culture Guide.
8. Mosmann T. Rapid colorimetric assay for cellular growth and survival: Application to proliferation and cytotoxicity assays. J Immunol Methods. 1983;65(1–2):55–63.
9. Skehan P, Storeng R, Scudiero D, et al. New colorimetric cytotoxicity assay for anticancer-drug screening. J Natl Cancer Inst. 1990;82(13):1107–1112.
10. Tominaga H, Ishiyama M, Ohseto F, et al. A water-soluble tetrazolium salt useful for colorimetric cell viability assay. Anal Commun. 1999;36:47–50.
11. Papadopoulos NG, Dedoussis GVZ, Spanakos G, et al. An improved fluorescence assay for the determination of lymphocyte-mediated cytotoxicity using calcein-AM. J Immunol Methods. 1994;177(1–2):101–111
12. Vermeulen K, Van Bockstaele DR, Berneman ZN. The cell cycle: A review of regulation, deregulation and therapeutic targets in cancer. Cell Prolif. 2003;36(3):131–149.
13. Otto T, Sicinski P. Cell cycle proteins as promising targets in cancer therapy. Nat Rev Cancer. 2017;17(2):93–115.
14. Mavrova AT, et al. Synthesis and antiproliferative activity of benzimidazole derivatives against human cancer cell lines. Eur J Med Chem. 2015;97:360–369.
15. Khan MS, et al. Benzimidazole–chalcone hybrids induce Gâ‚‚/M cell-cycle arrest and apoptosis in colorectal cancer cells. Bioorg Med Chem. 2021;39:116169.
16. Wang Y, et al. Benzimidazole–triazole hybrids inhibit PI3K/Akt signaling and induce Gâ‚€/G₁ arrest in HCT116 cells. Eur J Med Chem. 2023;250:115219.
17. Zhang L, et al. Fluorinated benzimidazole derivatives suppress Wnt/β-catenin signaling in colorectal cancer cells. Bioorg Chem. 2022;124:105825.